About TWINSTRAND BIOSCIENCES INC
TwinStrand Biosciences develops high-resolution next-generation sequencing (NGS) technology, specifically Duplex Sequencing, which significantly reduces sequencing error rates and detects rare genetic variants. The company's technology is used in mutagenesis and AML research, and has been validated by Health Canada.
High-resolution next-generation sequencing (NGS)Duplex Sequencing technology for detecting rare genetic variantsMutagenesis assay development and testingAML-related mutation identificationNitrosamine and mutagenesis testing services
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $18K | |
| Federal contract award | Department of Health and Human Services | $24K | |
| TWINSTRAND DUPLEX SEQUENCING MUTAGENESIS KIT | Department of Health and Human Services | $50K | |
| Federal contract award | Department of Health and Human Services | $24K | |
| Federal contract award | Department of Health and Human Services | $24K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to TWINSTRAND BIOSCIENCES INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.